PubRank

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Clinical Trial ID NCT01832870

PubWeight™ 17.28‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01832870

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
2 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013 1.09
3 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
4 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
5 The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev 2013 0.95
6 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
7 Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014 0.92
8 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
9 Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology 2014 0.90
10 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
11 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
12 Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother 2015 0.82
13 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
14 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014 0.79
15 Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 2016 0.78
16 Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016 0.76
17 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
18 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
19 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
20 Immunotherapy in genitourinary malignancies. Curr Opin Urol 2016 0.75
Next 100